BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 27678216)

  • 1. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment.
    Sirinawasatien A; Supawan P
    Medicine (Baltimore); 2024 May; 103(19):e38096. PubMed ID: 38728473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents.
    Goñi Esarte S; Juanbeltz R; Zozaya JM; Úriz JI; Castilla J; Herrero JI
    Gastroenterol Hepatol; 2020 May; 43(5):248-255. PubMed ID: 32192765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Response Monitoring of Chronic Hepatitis B Patients using Transient Elastography and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI).
    Tenggara IR; Lesmana CR; Gani RA
    Acta Med Indones; 2017 Jul; 49(3):220-226. PubMed ID: 29093232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
    Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
    Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
    Knop V; Hofmann WP; Buggisch P; Klinker H; Mauss S; Günther R; Hinrichsen H; Hüppe D; Pfeiffer-Vornkahl H; Simon KG; Berg T; Manns MP; Friedrich-Rust M;
    J Viral Hepat; 2019 Feb; 26(2):224-230. PubMed ID: 30315694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant decrease in liver stiffness detected by two dimensional shear-wave elastography after treatment with direct-acting antiviral agents in patients with chronic Hepatitis C.
    Yaraş S; Sezgin O; Üçbilek E; Özdoğan O; Altıntaş E
    Turk J Gastroenterol; 2020 Feb; 31(2):142-147. PubMed ID: 32141823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.
    Broquetas T; Herruzo-Pino P; Mariño Z; Naranjo D; Vergara M; Morillas RM; Forns X; Carrión JA
    Liver Int; 2021 Nov; 41(11):2733-2746. PubMed ID: 34525253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
    Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective non-invasive follow-up of liver fibrosis in patients with chronic hepatitis C.
    Crisan D; Radu C; Grigorescu MD; Lupsor M; Feier D; Grigorescu M
    J Gastrointestin Liver Dis; 2012 Dec; 21(4):375-82. PubMed ID: 23256120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
    Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
    BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
    Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
    J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
    D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
    J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.